Outcome according to treatment strategy for both training and validation cohort
| . | 5-y OS (95% CI), % . | 5-y PFS (95% CI), % . | 5-y TFS (95% CI), % . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| −MR . | +MR . | P . | −MR . | +MR . | P . | −MR . | +MR . | P . | |
| Training cohort | |||||||||
| All | 81 (76-85) | 89 (84-93) | .001 | 60 (55-65) | 72 (66-77) | <.001 | 76 (71-80) | 84 (79-84) | .002 |
| R-CHOP/CHOP-like* | 81 (73-88) | 93 (85-99) | .003 | 60 (52-69) | 77 (66-89) | .004 | 77 (69-85) | 88 (79-98) | .021 |
| R-CVP/CVP-like* | 81 (74-88) | 87 (79-96) | NS | 60 (51-68) | 67 (57-78) | NS | 76 (68-83) | 81 (72-91) | NS |
| Validation cohort | |||||||||
| All | 81 (69-88) | 89 (77-95) | .046 | 54 (42-64) | 70 (57-80) | .004 | 92 (82-96) | 93 (82-98) | NS |
| . | 5-y OS (95% CI), % . | 5-y PFS (95% CI), % . | 5-y TFS (95% CI), % . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| −MR . | +MR . | P . | −MR . | +MR . | P . | −MR . | +MR . | P . | |
| Training cohort | |||||||||
| All | 81 (76-85) | 89 (84-93) | .001 | 60 (55-65) | 72 (66-77) | <.001 | 76 (71-80) | 84 (79-84) | .002 |
| R-CHOP/CHOP-like* | 81 (73-88) | 93 (85-99) | .003 | 60 (52-69) | 77 (66-89) | .004 | 77 (69-85) | 88 (79-98) | .021 |
| R-CVP/CVP-like* | 81 (74-88) | 87 (79-96) | NS | 60 (51-68) | 67 (57-78) | NS | 76 (68-83) | 81 (72-91) | NS |
| Validation cohort | |||||||||
| All | 81 (69-88) | 89 (77-95) | .046 | 54 (42-64) | 70 (57-80) | .004 | 92 (82-96) | 93 (82-98) | NS |
Bold values represent significant P values (P < .05).
Pseudo values approach, nonproportional hazards.